Last reviewed · How we verify

Hawaii Pacific Health — Portfolio Competitive Intelligence Brief

Hawaii Pacific Health pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
ranibizumab intravitreal injection ranibizumab intravitreal injection phase 3 anti-VEGF agent VEGF-A Ophthalmology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Jaeb Center for Health Research · 1 shared drug class
  2. Moorfields Eye Hospital NHS Foundation Trust · 1 shared drug class
  3. Novartis · 1 shared drug class
  4. ONL Therapeutics · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Hawaii Pacific Health:

Cite this brief

Drug Landscape (2026). Hawaii Pacific Health — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/hawaii-pacific-health. Accessed 2026-05-17.

Related